Completed PHASE2 INTERVENTIONAL 4-arm NCT05631990

A Study to Evaluate the Efficacy and Safety of AD-209

A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension

Sponsor: Addpharma Inc.

Conditions Hypertension, Essential

Interventions AD-209 AD-209 placebo AD-209-1 placebo AD-209-1A AD-209-1B AD-209-1C

Updated 7 times since 2022 Last updated: Apr 3, 2024 Started: Apr 5, 2023 Primary completion: Nov 27, 2023 Completion: Nov 27, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hypertension, Essential and is currently completed. Addpharma Inc. leads this study, which shows 7 recorded versions since 2023 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2024 — Jul 2024 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jul 2023 — May 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

Jan 2023 — Jul 2023 [monthly]

Not Yet Recruiting PHASE2
Dec 2022 — Jan 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Addpharma Inc.

Data source: Addpharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea